Some investigators claim that EGFR mutations are prognostic rather than predictive, because subset analysis of TRIBUTE or INTACT trials (comparing platinum chemotherapy with chemotherapy plus EGFR-TKI) indicated that patients with lung cancer having EGFR mutations did better even in patients treated only with chemotherapy (Bell et al, 2005; Eberhard et al, 2005). The gene discussed is EGFR; the disease is lung carcinoma.